Adherence-resistance relationships to combination HIV antiretroviral therapy

被引：118

作者：

Bangsberg D.R. ^{[1
]}

Kroetz D.L. ^{[1
]}

Deeks S.G. ^{[1
]}

机构：

[1] Box 1372, San Francisco General Hospital, UCSF, San Francisco, CA 94110

来源：

Current HIV/AIDS Reports | 2007年 / 4卷 / 2期

关键词：

Lamivudine; Efavirenz; Nevirapine; Viral Suppression; Virologic Failure;

D O I：

10.1007/s11904-007-0010-0

中图分类号：

学科分类号：

摘要：

Early views on the relationship between adherence and resistance postulated a bell-shaped relationship that balanced selective drug pressure and improved viral suppression along a continuum of adherence. Although this conceptual relationship remains valid, recent data suggest that each regimen class may have different adherence-resistance relationships. These regimen-specific relationships are a function of the capacities of resistant virus to replicate at different levels of drug exposure, which are largely, but not entirely, determined by the impact of mutations on susceptibility of the virus and the impact of the mutations on the inherent ability of the virus to replicate efficiently. Specific patterns of adherence, such as treatment discontinuations, may influence adherence-resistance relationship to combination regimens comprised of medications with differing half-lives. Host genomics that alters antiretroviral drug distribution and metabolism may also impact adherence-resistance relationships. Optimal antiretroviral regimens should be constructed such that there is little overlap in the window of adherence that selects for antiretroviral drug resistance. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：65 / 72

页数：7

共 84 条

[1]

Hecht F.M., Grant R.M., Petropoulos C.J., Et al., Sexual transmission of an HIV-1 variant resistant to multiple reverse- transcriptase and protease inhibitors, N Engl J Med, 339, pp. 307-311, (1998)

[2]

Sontag D., Richardon L., Doctors withhold HIV pill regimen from some, New York Times, (1997)

[3]

Altice F.L., Friedland G.H., The era of adherence to HIV therapy [editorial], Ann Intern Med, 129, pp. 503-505, (1998)

[4]

Friedland G.H., Williams A., Attaining higher goals in HIV treatment: The central importance of adherence, AIDS, 13, SUPPL. 1, (1999)

[5]

Wainberg M.A., Friedland G., Public health implications of antiretroviral therapy and HIV drug resistance, JAMA, 279, pp. 1977-1983, (1998)

[6]

Bangsberg D., Tulsky J.P., Hecht F.M., Moss A.R., Protease inhibitors in the homeless, JAMA, 278, pp. 63-65, (1997)

[7]

Harries A.D., Nyangulu D.S., Hargreaves N.J., Et al., Preventing antiretroviral anarchy in sub-Saharan Africa, Lancet, 358, pp. 410-414, (2001)

[8]

Popp D., Fisher J.D., First, do no harm: A call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world, AIDS, 16, pp. 676-678, (2002)

[9]

Stevens W., Kaye S., Corrah T., Antiretroviral therapy in Africa, BMJ, 328, pp. 280-282, (2004)

[10]

Bangsberg D.R., Moss A.R., Deeks S.G., Paradoxes of HIV antiretroviral adherence and drug resistance, J Antimicrob Chemother, 53, pp. 696-699, (2004)

← 1 2 3 4 5 6 7 8 9 →